Cryofocus Medtech (Shanghai) Co., Ltd. announced its unaudited interim results for the six months ended June 30, 2025, showing robust growth and significant operational optimization. The company recorded a 162.4% increase in revenue, driven primarily by its respiratory intervention products, reaching RMB51.1 million from RMB19.5 million in the same period of 2024. This growth is attributed to the Malignant Stenosis Cryoablation System and the Cryoadhesion System, with the former recently approved by China’s National Medical Products Administration and the latter already commercialized. The Asthma Cryoablation System also received a 'Breakthrough Medical Device' designation from the U.S. FDA, marking a significant step for global market expansion.\n\nCryofocus has developed a competitive respiratory intervention portfolio addressing various conditions like malignant stenosis, asthma, COPD, and more. The company's technology platforms, including liquid nitrogen-based cryoablation and advanced flexible catheter technology, enable precise and minimally invasive treatments. Beyond respiratory products, Cryofocus has expanded into vascular interventions, NOTES, and non-cryotherapy products, creating a diversified 'one-platform, multi-therapy' model.\n\nFinancially, Cryofocus demonstrated resilience with a gross profit of RMB34.3 million and a gross profit margin of 67.1%. The company reduced R&D expenses significantly, narrowing its period loss, while cash reserves increased to RMB63.7 million. Sales network development also saw a substantial increase in expenses, indicating proactive resource allocation.\n\nBenchmarking against Inspire Medical Systems, Cryofocus's valuation potential is highlighted, with significant upside potential due to its technological capabilities and diversified product pipeline. The company plans to advance clinical development, deepen its focus on minimally invasive interventional cryotherapy, and expand globally. Cryofocus is transitioning from an R&D-driven model to a dual-engine model integrating R&D and commercialization, aiming to become a global platform for minimally invasive interventional cryotherapy medical devices.

Cryofocus Medtech Achieves Record Interim Results with 162% Revenue Surge Driven by Respiratory Intervention Products

Cryofocus Medtech (Shanghai) Co., Ltd. reported a 162.4% increase in revenue for the six months ended June 30, 2025, reaching RMB51.1 million, primarily driven by its respiratory intervention products such as the Malignant Stenosis Cryoablation System and Cryoadhesion System. The Malignant Stenosis Cryoablation System received approval from China’s National Medical Products Administration, while the Cryoadhesion System is already commercialized. The Asthma Cryoablation System was designated a 'Breakthrough Medical Device' by the U.S. FDA, supporting global market expansion. The company achieved a gross profit margin of 67.1% and increased cash reserves to RMB63.7 million, despite reducing R&D expenses. Cryofocus is transitioning from an R&D-driven model to a dual-engine model integrating R&D and commercialization, aiming to become a global leader in minimally invasive interventional cryotherapy medical devices.